Vascular Dementia and Parkinsonism

  • Laura Silveira-MoriyamaEmail author
  • Egberto R. Barbosa
  • Paulo Caramelli
  • Jan Zijlmans
  • Andrew J. Lees


Cerebrovascular disease is a leading cause of mortality and morbidity worldwide. Its clinical manifestations vary from acute neurological deficit to stepwise or slowly progressive chronic deficits. Although originally described as separate entities, vascular dementia and vascular parkinsonism are overlapping spectrums of cognitive and extrapyramidal manifestations associated with subcortical vascular damage. In this chapter, we discuss the main concepts underlying the historical concepts of Binswanger encephalopathy and lower-body parkinsonism, present the main features of vascular dementia and vascular parkinsonism, summarize recommendations for clinical management, and close with suggestions for future research in these prevalent and often neglected conditions.


Vascular dementia Vascular parkinsonism Lower-body parkinsonism Binswanger encephalopathy Cerebrovascular disease 


  1. Ballard CG, Burton EJ, Barber R, Stephens S, Kenny RA, Kalaria RN, O’brien JT. NINDS AIREN neuroimaging criteria do not distinguish stroke patients with and without dementia. Neurology. 2004;63(6):983–8.PubMedCrossRefGoogle Scholar
  2. Ballard C, Sauter M, Scheltens P, He Y, Barkhof F, van Straaten EC, van der Flier WM, Hsu C, Wu S, Lane R. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin. 2008;24(9):2561–74.PubMedCrossRefGoogle Scholar
  3. Black S, Román GC, Geldmacher DS, Salloway S, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R, Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003;34(10):2323–30.PubMedCrossRefGoogle Scholar
  4. Bohnen NI, Muller ML, Zarzhevsky N, Koeppe RA, Bogan CW, Kilbourn MR, et al. Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson’s disease. Brain. 2011;134(Pt 8):2358–65.PubMedCentralPubMedCrossRefGoogle Scholar
  5. Bradley WG, Daroff RB, Fenichel G, Jankovic J. Neurology in clinical practice. Philadelphia: Butterworth-Heinemann/Elsevier Saunders; 2008.Google Scholar
  6. Brewster PW, Mcdowell I, Moineddin R, Tierney MC. Differential prediction of vascular dementia and Alzheimer’s disease in nondemented older adults within 5 years of initial testing. Alzheimers Dement. 2012;8(6):528–35.PubMedCrossRefGoogle Scholar
  7. Critchley M. Arteriosclerotic parkinsonism. Brain. 1929;52:23–83.CrossRefGoogle Scholar
  8. Critchley M. Arteriosclerotic pseudo-parkinsonism. Tunbridge Wells: Pitman Medical; 1981.Google Scholar
  9. Demirkiran M, Bozdemir H, Sarica Y. Vascular parkinsonism: a distinct, heterogeneous clinical entity. Acta Neurol Scand. 2001;104:63–7.PubMedCrossRefGoogle Scholar
  10. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomized trial. Lancet. 2002;359:1283–90.PubMedCrossRefGoogle Scholar
  11. Erkinjuntti T, Roman G, Gauthier S. Treatment of vascular dementia–evidence from clinical trials with cholinesterase inhibitors. J Neurol Sci. 2004;226:63–6.PubMedCrossRefGoogle Scholar
  12. Fitzgerald PM, Jankovic J. Lower body parkinsonism: evidence for vascular etiology. Mov Disord. 1989;4:249–60.PubMedCrossRefGoogle Scholar
  13. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51:745–52.PubMedCentralPubMedCrossRefGoogle Scholar
  14. Glass P. Clinical features of vascular parkinsonism in pathologically confirmed cases. MSc thesis, UCL Institute of Neurology. London, 2012.Google Scholar
  15. Glass PG, Lees AJ, Bacellar A, Zijlmans J, Katzenschlager R, Silveira-Moriyama L. The clinical features of pathologically confirmed vascular parkinsonism. J Neurol Neurosurg Psychiatry. 2012;83(10):1027–9.PubMedCrossRefGoogle Scholar
  16. Gorelick PB, Pantoni L. Advances in vascular cognitive impairment. Stroke. 2013;44(2):307–8.PubMedCrossRefGoogle Scholar
  17. Hachinski VC, Lassen NA. Multi-infarct dementia: a cause of mental deterioration in the elderly. Lancet. 1974;2:207–10.PubMedCrossRefGoogle Scholar
  18. Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol. 1975;32:632–7.PubMedCrossRefGoogle Scholar
  19. Jellinger KA. Vascular parkinsonism-neuropathological findings. Acta Neurol Scand. 2002;105:414–5.PubMedCrossRefGoogle Scholar
  20. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomized controlled trials. Lancet Neurol. 2007;6:782–92.PubMedCrossRefGoogle Scholar
  21. Katzenschlager R, Zijlmans J, Evans A, Watt H, Lees AJ. Olfactory function distinguishes vascular parkinsonism from Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75:1749–52.PubMedCentralPubMedCrossRefGoogle Scholar
  22. Mcshane R, Areosa AS, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2011;(3):CD003154.pub1.Google Scholar
  23. Mcguiness B, Ohare J, Craig D, et al. Statins for the treatment of dementia. Cochrane Database Syst Rev. 2010;(8):CD007514.Google Scholar
  24. Moroney JT, Bagiella F, Desmond DW, et al. Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology. 1997;49:1096–105.PubMedCrossRefGoogle Scholar
  25. Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, Schrag A. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol. 2012;72(6):893–901.PubMedCentralPubMedCrossRefGoogle Scholar
  26. Pearce JMS. Binswanger’s “encephalitis subcorticalis chronica progressiva”. J Neurol Neurosurg Psychiatry. 1997;63:308. doi: 10.1136/jnnp.63.3.308.PubMedCentralPubMedCrossRefGoogle Scholar
  27. Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7:683–9.PubMedCrossRefGoogle Scholar
  28. Rampello L, Alvano A, Battaglia G, Raffaele R, Vecchio I, Malaguarnera M. Different clinical and evolutional patterns in late idiopathic and vascular parkinsonism. J Neurol. 2005;252:1045–9.PubMedCrossRefGoogle Scholar
  29. Román CG, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINCDS-AIREN International Workshop. Neurology. 1993;43:250–60.PubMedCrossRefGoogle Scholar
  30. Román GC. Facts, myths, and controversies in vascular dementia. J Neurol Sci. 2004;226(1–2):49–52.PubMedCrossRefGoogle Scholar
  31. Sabbagh MN, Sparks DL. Statins to treat Alzheimer’s disease: an incomplete story. Expert Rev Neurother. 2012;12(1):27–30. doi: 10.1586/ern.11.171.PubMedCrossRefGoogle Scholar
  32. Santangelo G, Vitale C, Trojano L, de Gaspari D, Bilo L, Antonini A, Barone P. Differential neuropsychological profiles in Parkinsonian patients with or without vascular lesions. Mov Disord. 2010;25:50–6.PubMedCrossRefGoogle Scholar
  33. Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;(2):CD008191.Google Scholar
  34. Tang WK, Chan SS, Chiu HF, Ungvari GS, Wong KS, Kwok TC, Mok V, Wong KT, Richards PS, Ahuja AT. Impact of applying NINDS-AIREN criteria of probable vascular dementia to clinical and radiological characteristics of a stroke cohort with dementia. Cerebrovasc Dis. 2004;18(2):98–103.PubMedCrossRefGoogle Scholar
  35. Vale TC, Barbosa MT, Caramelli P, Cardoso F. Vascular parkinsonism and cognitive impairment. Dement Neuropsychol. 2012;6(3):137–44.Google Scholar
  36. Wilcock G, Möbius HJ, Stöffler A, MMM 500 group. A double-blind, placebo-controlled, multicentre study of memantine in mild to moderate vascular dementia (MMM 500). Int Clin Psychopharmacol. 2002;17:197–305.CrossRefGoogle Scholar
  37. Winikates J, Jankovic J. Clinical correlates of vascular parkinsonism. Arch Neurol. 1999;56:98–102.PubMedCrossRefGoogle Scholar
  38. Witt K, Borsch K, Daniels C, et al. Neuropsychological consequences of endarterectomy and endovascular angioplasty with stent placement for treatment of symptomatic carotid stenosis. A prospective randomized study. J Neurol. 2007;254:1524–32.PubMedCrossRefGoogle Scholar
  39. Zijlmans JC, Daniel SE, Hughes AJ, Revesz T, Lees AJ. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord. 2004a;19:630–40.PubMedCrossRefGoogle Scholar
  40. Zijlmans JC, Katzenschlager R, Daniel SE, Lees AJ. The L-dopa response in vascular parkinsonism. J Neurol Neurosurg Psychiatry. 2004b;75:545–7.PubMedCentralPubMedCrossRefGoogle Scholar
  41. Zijlmans J, Evans A, Fontes F, et al. [123I] FP-CIT spect study in vascular parkinsonism and Parkinson’s disease. Mov Disord. 2007;22:1278–85.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Laura Silveira-Moriyama
    • 1
    • 2
    Email author
  • Egberto R. Barbosa
    • 3
  • Paulo Caramelli
    • 4
  • Jan Zijlmans
    • 5
  • Andrew J. Lees
    • 1
  1. 1.National Hospital for Neurology and Neurosurgery, Reta Lila Weston Institute, UCL Institute of NeurologyLondonUK
  2. 2.Neurology Department, FCMUniversity of Campinas, UNICAMP, Hospital Das ClinicasCampinasBrazil
  3. 3.Department of NeurologyUniversity of Sao Paulo School of Medicine, Hospital Das ClinicasSao PauloBrazil
  4. 4.Department of Internal Medicine, Faculty of MedicineFederal University of Minas GeraisBelo HorizonteBrazil
  5. 5.Department of NeurologyAmphia HospitalBreda, NAThe Netherlands

Personalised recommendations